Description
Pharmaceutical leader in clinical development and medical affairs with experience in Phases 1 through 4 of clinical development, commercialization and medical affairs across therapeutic areas (CNS, Rheumatology, Immunology, Pulmonary). These activities included FDA interactions and document preparations, line extension and commercialization of pharmaceutical products, medical monitoring, safety assessment, pharmacokinetic evaluation, KOL relations, training sales and MSL teams, managing a scientific grant program, and business development activities. Expert at leading interdisciplinary teams in a matrix environment. Frequently provided scientific representation of the company in organizations and meetings. Medical lead on successful development of Krystexxa, approved in 2010. Extensive fellowship training in schizophrenia and neuroimmunovirology with expertise in clinical and pre-clinical research methodology. Experienced leader in clinical care of major mental disorders, teaching and research. Trained at Yale University Department of Psychiatry (West Haven VAMC, Yale New Haven Hospital and the Yale Psychiatric Institute). Board certified in psychiatry. Extensive academic and patient care background at the Maryland Psychiatric Research Center, Johns Hopkins University, and the University of Mississippi Medical Center. Served as an independent researcher, medical student and resident supervisor, course leader, and departmental representative on major university committees. Examiner, American Board of Psychiatry and Neurology, Inc.
Accomplishments
Highlights:
Keywords
